241 related articles for article (PubMed ID: 24994606)
1. Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.
Aslanyan MG; Kroeze LI; Langemeijer SM; Koorenhof-Scheele TN; Massop M; van Hoogen P; Stevens-Linders E; van de Locht LT; Tönnissen E; van der Heijden A; da Silva-Coelho P; Cilloni D; Saglio G; Marie JP; Tang R; Labar B; Amadori S; Muus P; Willemze R; Marijt EW; de Witte T; van der Reijden BA; Suciu S; Jansen JH
Ann Hematol; 2014 Aug; 93(8):1401-12. PubMed ID: 24994606
[TBL] [Abstract][Full Text] [Related]
2. Characterization of acute myeloid leukemia based on levels of global hydroxymethylation.
Kroeze LI; Aslanyan MG; van Rooij A; Koorenhof-Scheele TN; Massop M; Carell T; Boezeman JB; Marie JP; Halkes CJ; de Witte T; Huls G; Suciu S; Wevers RA; van der Reijden BA; Jansen JH;
Blood; 2014 Aug; 124(7):1110-8. PubMed ID: 24986689
[TBL] [Abstract][Full Text] [Related]
3. 5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia.
Ahn JS; Kim HJ; Kim YK; Lee SS; Ahn SY; Jung SH; Yang DH; Lee JJ; Park HJ; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Michael S; Minden MD; Kim DD
Oncotarget; 2017 Jan; 8(5):8305-8314. PubMed ID: 28039446
[TBL] [Abstract][Full Text] [Related]
4. A distinct immunophenotype identifies a subset of NPM1-mutated AML with TET2 or IDH1/2 mutations and improved outcome.
Mason EF; Kuo FC; Hasserjian RP; Seegmiller AC; Pozdnyakova O
Am J Hematol; 2018 Aug; 93(4):504-510. PubMed ID: 29274134
[TBL] [Abstract][Full Text] [Related]
5. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K
J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270
[TBL] [Abstract][Full Text] [Related]
6. Cooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1, TET2, IDH1, IDH2, and DNMT3A.
Liang DC; Liu HC; Yang CP; Jaing TH; Hung IJ; Yeh TC; Chen SH; Hou JY; Huang YJ; Shih YS; Huang YH; Lin TH; Shih LY
Blood; 2013 Apr; 121(15):2988-95. PubMed ID: 23365461
[TBL] [Abstract][Full Text] [Related]
7. Molecular genetics of acute myeloid leukemia: clinical implications and opportunities for integrating genomics into clinical practice.
Abdel-Wahab O
Hematology; 2012 Apr; 17 Suppl 1():S39-42. PubMed ID: 22507776
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of novel mutations in epigenetic modifiers in AML.
Abdel-Wahab O; Patel J; Levine RL
Hematol Oncol Clin North Am; 2011 Dec; 25(6):1119-33. PubMed ID: 22093580
[TBL] [Abstract][Full Text] [Related]
9. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
Sasaki K; Kanagal-Shamanna R; Montalban-Bravo G; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Patel K; Soltysiak KA; Cortes J; Kantarjian HM; Garcia-Manero G
Cancer; 2020 Feb; 126(4):765-774. PubMed ID: 31742675
[TBL] [Abstract][Full Text] [Related]
10. Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.
Falini B; Sportoletti P; Brunetti L; Martelli MP
Br J Haematol; 2015 Aug; 170(3):305-22. PubMed ID: 25891481
[TBL] [Abstract][Full Text] [Related]
11. TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia.
Zhang TJ; Zhou JD; Yang DQ; Wang YX; Wen XM; Guo H; Yang L; Lian XY; Lin J; Qian J
J Cell Physiol; 2018 Aug; 233(8):5838-5846. PubMed ID: 29219176
[TBL] [Abstract][Full Text] [Related]
12. Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia.
Wakita S; Yamaguchi H; Omori I; Terada K; Ueda T; Manabe E; Kurosawa S; Iida S; Ibaraki T; Sato Y; Todoroki T; Hirakawa T; Ryotokuji T; Arai K; Kitano T; Mitamura Y; Kosaka F; Dan K; Inokuchi K
Leukemia; 2013 Apr; 27(5):1044-52. PubMed ID: 23135354
[TBL] [Abstract][Full Text] [Related]
13. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
[TBL] [Abstract][Full Text] [Related]
14. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia.
Rampal R; Alkalin A; Madzo J; Vasanthakumar A; Pronier E; Patel J; Li Y; Ahn J; Abdel-Wahab O; Shih A; Lu C; Ward PS; Tsai JJ; Hricik T; Tosello V; Tallman JE; Zhao X; Daniels D; Dai Q; Ciminio L; Aifantis I; He C; Fuks F; Tallman MS; Ferrando A; Nimer S; Paietta E; Thompson CB; Licht JD; Mason CE; Godley LA; Melnick A; Figueroa ME; Levine RL
Cell Rep; 2014 Dec; 9(5):1841-1855. PubMed ID: 25482556
[TBL] [Abstract][Full Text] [Related]
15. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
Figueroa ME; Abdel-Wahab O; Lu C; Ward PS; Patel J; Shih A; Li Y; Bhagwat N; Vasanthakumar A; Fernandez HF; Tallman MS; Sun Z; Wolniak K; Peeters JK; Liu W; Choe SE; Fantin VR; Paietta E; Löwenberg B; Licht JD; Godley LA; Delwel R; Valk PJ; Thompson CB; Levine RL; Melnick A
Cancer Cell; 2010 Dec; 18(6):553-67. PubMed ID: 21130701
[TBL] [Abstract][Full Text] [Related]
16. [Research progress on genes associated with transformation of myelodysplastic syndromes to acute myeloid leukemia].
Zhu C; Ma Y; Xu XP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):873-8. PubMed ID: 24989313
[TBL] [Abstract][Full Text] [Related]
17. CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.
Grossmann V; Haferlach C; Nadarajah N; Fasan A; Weissmann S; Roller A; Eder C; Stopp E; Kern W; Haferlach T; Kohlmann A; Schnittger S
Br J Haematol; 2013 Jun; 161(5):649-658. PubMed ID: 23521373
[TBL] [Abstract][Full Text] [Related]
18. Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation.
Jentzsch M; Grimm J; Bill M; Küpper J; Backhaus D; Brauer D; Schulz J; Franke GN; Vucinic V; Niederwieser D; Platzbecker U; Schwind S
Bone Marrow Transplant; 2021 Oct; 56(10):2610-2612. PubMed ID: 34267355
[No Abstract] [Full Text] [Related]
19. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group.
Ho PA; Kutny MA; Alonzo TA; Gerbing RB; Joaquin J; Raimondi SC; Gamis AS; Meshinchi S
Pediatr Blood Cancer; 2011 Aug; 57(2):204-9. PubMed ID: 21504050
[TBL] [Abstract][Full Text] [Related]
20. Mutations in TET2 and DNMT3A genes are associated with changes in global and gene-specific methylation in acute myeloid leukemia.
Ponciano-Gómez A; Martínez-Tovar A; Vela-Ojeda J; Olarte-Carrillo I; Centeno-Cruz F; Garrido E
Tumour Biol; 2017 Oct; 39(10):1010428317732181. PubMed ID: 28992762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
